<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:40d86869-7a63-4cf8-9044-c6fd2cae789e,g:cffef770-2cec-4fbd-a147-b09da8e4c413-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/Cover" xlink:type="simple" xlink:href="abus-20201231.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="abus-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ddf0f8ad-58b7-4810-af4a-7fed630b53cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e47b0fbd-429e-4492-b98c-5bc44de5e75f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ddf0f8ad-58b7-4810-af4a-7fed630b53cd" xlink:to="loc_us-gaap_AssetsCurrent_e47b0fbd-429e-4492-b98c-5bc44de5e75f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_05ffebfd-5454-46f3-9ef0-dc9c29a8325a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ddf0f8ad-58b7-4810-af4a-7fed630b53cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_05ffebfd-5454-46f3-9ef0-dc9c29a8325a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_47471115-14df-414a-8992-c19a5f7667f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ddf0f8ad-58b7-4810-af4a-7fed630b53cd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_47471115-14df-414a-8992-c19a5f7667f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_83388bf3-d70e-4dc6-b423-47e47f666e11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ddf0f8ad-58b7-4810-af4a-7fed630b53cd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_83388bf3-d70e-4dc6-b423-47e47f666e11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ec79a791-e293-443d-bc3e-8ec5390c3c96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b84da949-60a6-4b6a-93fa-7a942340e365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ec79a791-e293-443d-bc3e-8ec5390c3c96" xlink:to="loc_us-gaap_Liabilities_b84da949-60a6-4b6a-93fa-7a942340e365" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0829c542-8b68-45b9-b375-5f83f48cfffb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ec79a791-e293-443d-bc3e-8ec5390c3c96" xlink:to="loc_us-gaap_StockholdersEquity_0829c542-8b68-45b9-b375-5f83f48cfffb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_79150f70-b3c5-462b-9be1-d29fbf846a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_abdf38f0-3e4f-4406-9bb6-cef4f2d40195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_79150f70-b3c5-462b-9be1-d29fbf846a13" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_abdf38f0-3e4f-4406-9bb6-cef4f2d40195" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_207f9618-5c00-4c50-b377-3d3a60a6fb2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_79150f70-b3c5-462b-9be1-d29fbf846a13" xlink:to="loc_us-gaap_ShortTermInvestments_207f9618-5c00-4c50-b377-3d3a60a6fb2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4f01a15c-4345-44ce-a7d6-9c1c026cb291" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_79150f70-b3c5-462b-9be1-d29fbf846a13" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4f01a15c-4345-44ce-a7d6-9c1c026cb291" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3fdc33f2-df5e-4dd9-a10f-c88f2ba10c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_79150f70-b3c5-462b-9be1-d29fbf846a13" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3fdc33f2-df5e-4dd9-a10f-c88f2ba10c6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_480a39f2-7915-40ed-8e68-3d04a56eb455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1a3a5a9e-a9f0-4908-95e7-da236a037220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_480a39f2-7915-40ed-8e68-3d04a56eb455" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1a3a5a9e-a9f0-4908-95e7-da236a037220" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c99c1c71-8415-4257-95ff-87ce8fa1856d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_480a39f2-7915-40ed-8e68-3d04a56eb455" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c99c1c71-8415-4257-95ff-87ce8fa1856d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8b06cc65-6572-4f55-b5f7-dbe41b2af652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_480a39f2-7915-40ed-8e68-3d04a56eb455" xlink:to="loc_us-gaap_LiabilitiesCurrent_8b06cc65-6572-4f55-b5f7-dbe41b2af652" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_65e8160d-1298-4cd6-89be-44f809643e36" xlink:href="abus-20201231.xsd#abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_480a39f2-7915-40ed-8e68-3d04a56eb455" xlink:to="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_65e8160d-1298-4cd6-89be-44f809643e36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_75b82446-edc1-4c9a-a5ad-3d0f61251ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e0e0960b-120a-4be7-a9f9-30bbc9686084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_75b82446-edc1-4c9a-a5ad-3d0f61251ca6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e0e0960b-120a-4be7-a9f9-30bbc9686084" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_5ec19180-21db-4239-b4c3-9563f3d0f520" xlink:href="abus-20201231.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_75b82446-edc1-4c9a-a5ad-3d0f61251ca6" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_5ec19180-21db-4239-b4c3-9563f3d0f520" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d2b3766e-e4a2-4d2e-a123-36638dd532da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_75b82446-edc1-4c9a-a5ad-3d0f61251ca6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d2b3766e-e4a2-4d2e-a123-36638dd532da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9336c73c-92a6-48da-a8a5-d1e5fa661ac7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount_a151531e-4433-4935-b7a6-5e6bc95a7b68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9336c73c-92a6-48da-a8a5-d1e5fa661ac7" xlink:to="loc_us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount_a151531e-4433-4935-b7a6-5e6bc95a7b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7152fe11-82e8-4aa3-827f-4cf1f50caa4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9336c73c-92a6-48da-a8a5-d1e5fa661ac7" xlink:to="loc_us-gaap_CommonStockValue_7152fe11-82e8-4aa3-827f-4cf1f50caa4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_bf0849c6-0f86-4374-a912-b00a9ef3ba14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9336c73c-92a6-48da-a8a5-d1e5fa661ac7" xlink:to="loc_us-gaap_AdditionalPaidInCapital_bf0849c6-0f86-4374-a912-b00a9ef3ba14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aac8ad33-7b50-48c7-91b8-b2bbd9b90391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9336c73c-92a6-48da-a8a5-d1e5fa661ac7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aac8ad33-7b50-48c7-91b8-b2bbd9b90391" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_07799981-4dea-4fef-b8b3-50293ef7267e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9336c73c-92a6-48da-a8a5-d1e5fa661ac7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_07799981-4dea-4fef-b8b3-50293ef7267e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="abus-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="abus-20201231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3cb9210a-06f6-40b7-9446-f14f3805891d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_8a62536e-461a-4049-a582-a05fcada02a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3cb9210a-06f6-40b7-9446-f14f3805891d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_8a62536e-461a-4049-a582-a05fcada02a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_efea8328-cfa5-43e4-81c5-6c752270d4f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3cb9210a-06f6-40b7-9446-f14f3805891d" xlink:to="loc_us-gaap_NetIncomeLoss_efea8328-cfa5-43e4-81c5-6c752270d4f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest_10be664b-94f9-4012-a83f-e36d2726c45e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3cb9210a-06f6-40b7-9446-f14f3805891d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest_10be664b-94f9-4012-a83f-e36d2726c45e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a403dd4f-8377-4606-9660-a6eec365f133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_95069bba-690e-472a-8402-5078a591ef63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a403dd4f-8377-4606-9660-a6eec365f133" xlink:to="loc_us-gaap_NetIncomeLoss_95069bba-690e-472a-8402-5078a591ef63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_d3d171b6-ba3b-4c35-a268-8211c669e3db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a403dd4f-8377-4606-9660-a6eec365f133" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_d3d171b6-ba3b-4c35-a268-8211c669e3db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a44cb4ed-9849-4506-af50-e2f2cfae5123" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_7deb5c21-4f60-47fb-88e0-1835aed59d58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a44cb4ed-9849-4506-af50-e2f2cfae5123" xlink:to="loc_us-gaap_RestructuringCharges_7deb5c21-4f60-47fb-88e0-1835aed59d58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a2758602-6bc7-4d04-8785-07e2c00c3acc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a44cb4ed-9849-4506-af50-e2f2cfae5123" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a2758602-6bc7-4d04-8785-07e2c00c3acc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_c8fed55b-5a2d-4357-bbd5-65189b8c30c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalFees"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a44cb4ed-9849-4506-af50-e2f2cfae5123" xlink:to="loc_us-gaap_LegalFees_c8fed55b-5a2d-4357-bbd5-65189b8c30c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_85d3fd00-626e-4943-bea0-eace16d26ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a44cb4ed-9849-4506-af50-e2f2cfae5123" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_85d3fd00-626e-4943-bea0-eace16d26ddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b36620f2-d27f-4dce-886c-87ea40838ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a44cb4ed-9849-4506-af50-e2f2cfae5123" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b36620f2-d27f-4dce-886c-87ea40838ea8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_bd43f665-efb6-428f-b1d2-f998c1f8c3fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a44cb4ed-9849-4506-af50-e2f2cfae5123" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_bd43f665-efb6-428f-b1d2-f998c1f8c3fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b728c863-587e-4eae-8c1a-06cad235cd05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a44cb4ed-9849-4506-af50-e2f2cfae5123" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b728c863-587e-4eae-8c1a-06cad235cd05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c038f81e-2467-4700-9b59-f28d0028b472" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a44cb4ed-9849-4506-af50-e2f2cfae5123" xlink:to="loc_us-gaap_Depreciation_c038f81e-2467-4700-9b59-f28d0028b472" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_89ab5ead-7261-4938-9873-6eab0ae38de4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0a80384a-301a-4110-be26-e1722bc327bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_89ab5ead-7261-4938-9873-6eab0ae38de4" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0a80384a-301a-4110-be26-e1722bc327bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ca7c03f9-976a-4dd9-b0be-89ad763ebe39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_89ab5ead-7261-4938-9873-6eab0ae38de4" xlink:to="loc_us-gaap_InterestExpense_ca7c03f9-976a-4dd9-b0be-89ad763ebe39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_8fa72ad1-e9b0-46fe-aa12-b6adf7caeb6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_89ab5ead-7261-4938-9873-6eab0ae38de4" xlink:to="loc_us-gaap_InvestmentIncomeInterest_8fa72ad1-e9b0-46fe-aa12-b6adf7caeb6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5c48a669-a021-4aed-b73a-a3cb864d3c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_89ab5ead-7261-4938-9873-6eab0ae38de4" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5c48a669-a021-4aed-b73a-a3cb864d3c3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d24d949c-a087-4115-a225-72b8513e962a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4e05b4f9-c4d9-4d7e-8348-5fa2188c88d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d24d949c-a087-4115-a225-72b8513e962a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4e05b4f9-c4d9-4d7e-8348-5fa2188c88d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c211250f-e9ac-4ebc-b38a-ebb68b36a170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d24d949c-a087-4115-a225-72b8513e962a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c211250f-e9ac-4ebc-b38a-ebb68b36a170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0bebd5bb-f748-4ea8-afc3-109c0c30a39f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_761965bc-d693-4a6e-a85e-31ca02a39488" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0bebd5bb-f748-4ea8-afc3-109c0c30a39f" xlink:to="loc_us-gaap_OperatingExpenses_761965bc-d693-4a6e-a85e-31ca02a39488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_949f1db2-44b4-48ee-93ec-1a96643c203b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0bebd5bb-f748-4ea8-afc3-109c0c30a39f" xlink:to="loc_us-gaap_Revenues_949f1db2-44b4-48ee-93ec-1a96643c203b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementofStockholdersEquity" xlink:type="simple" xlink:href="abus-20201231.xsd#ConsolidatedStatementofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="abus-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f11f93cd-5d9d-463d-9ce3-02329c53cca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_a7dd814f-63c9-4775-8635-be669d07fc72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f11f93cd-5d9d-463d-9ce3-02329c53cca2" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_a7dd814f-63c9-4775-8635-be669d07fc72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e84369db-0680-4c8f-8f67-ce351a657c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f11f93cd-5d9d-463d-9ce3-02329c53cca2" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e84369db-0680-4c8f-8f67-ce351a657c0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2afef079-0962-4e00-a89c-5fe6dcd611cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f11f93cd-5d9d-463d-9ce3-02329c53cca2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2afef079-0962-4e00-a89c-5fe6dcd611cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_ddc377e7-3724-44ad-abcc-7da01105a827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f11f93cd-5d9d-463d-9ce3-02329c53cca2" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_ddc377e7-3724-44ad-abcc-7da01105a827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_e8a2fb5d-ed87-4273-81f4-37375f5ab01f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f11f93cd-5d9d-463d-9ce3-02329c53cca2" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_e8a2fb5d-ed87-4273-81f4-37375f5ab01f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_616d37c7-be3d-40a7-855e-ff6ff67b0cc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3016154b-0c64-4b84-a849-8740be0ecad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_616d37c7-be3d-40a7-855e-ff6ff67b0cc4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3016154b-0c64-4b84-a849-8740be0ecad0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fcfe29cd-ba52-4589-901f-4356dd58c626" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_616d37c7-be3d-40a7-855e-ff6ff67b0cc4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fcfe29cd-ba52-4589-901f-4356dd58c626" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_85c506b7-39e6-4228-8b65-516ab9844a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_616d37c7-be3d-40a7-855e-ff6ff67b0cc4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_85c506b7-39e6-4228-8b65-516ab9844a9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ec936d0-ff2e-4fc4-8d9c-e5a009bb2c09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_616d37c7-be3d-40a7-855e-ff6ff67b0cc4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ec936d0-ff2e-4fc4-8d9c-e5a009bb2c09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9109224-9be5-4375-b761-58e54696796b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a181b6ca-ed36-4856-9173-cd48b37b35a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9109224-9be5-4375-b761-58e54696796b" xlink:to="loc_us-gaap_NetIncomeLoss_a181b6ca-ed36-4856-9173-cd48b37b35a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9beded0a-f14b-4fdc-a922-2c18eba36116" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9109224-9be5-4375-b761-58e54696796b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9beded0a-f14b-4fdc-a922-2c18eba36116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_3c6fe672-788a-4513-a9fd-d88584781c57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9109224-9be5-4375-b761-58e54696796b" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_3c6fe672-788a-4513-a9fd-d88584781c57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ed739abe-9895-49b1-af40-ae011a5364b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9109224-9be5-4375-b761-58e54696796b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ed739abe-9895-49b1-af40-ae011a5364b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_17687ed5-0656-43b1-b6fb-3ee27afa258c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9109224-9be5-4375-b761-58e54696796b" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_17687ed5-0656-43b1-b6fb-3ee27afa258c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_94ef14b5-917e-404a-8ddf-217e89e89e05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9109224-9be5-4375-b761-58e54696796b" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_94ef14b5-917e-404a-8ddf-217e89e89e05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_92dab8b5-c05c-41bd-9803-8e55d49fdf34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9109224-9be5-4375-b761-58e54696796b" xlink:to="loc_us-gaap_ShareBasedCompensation_92dab8b5-c05c-41bd-9803-8e55d49fdf34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Netequityinvestmentgainorloss_ab8d3ace-6465-43dd-be73-c0271f1d6ea8" xlink:href="abus-20201231.xsd#abus_Netequityinvestmentgainorloss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9109224-9be5-4375-b761-58e54696796b" xlink:to="loc_abus_Netequityinvestmentgainorloss_ab8d3ace-6465-43dd-be73-c0271f1d6ea8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1924f466-f51c-450c-9259-c3e6187e4646" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9109224-9be5-4375-b761-58e54696796b" xlink:to="loc_us-gaap_Depreciation_1924f466-f51c-450c-9259-c3e6187e4646" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_28ba12f7-9cf5-4032-a655-9f967eba49b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9109224-9be5-4375-b761-58e54696796b" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_28ba12f7-9cf5-4032-a655-9f967eba49b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6162c003-6c3e-42a7-b9e6-25c9d8108ba4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9109224-9be5-4375-b761-58e54696796b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6162c003-6c3e-42a7-b9e6-25c9d8108ba4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_aafd2adf-b841-4753-beb3-d059dc9a3d70" xlink:href="abus-20201231.xsd#abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9109224-9be5-4375-b761-58e54696796b" xlink:to="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_aafd2adf-b841-4753-beb3-d059dc9a3d70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b45d7eba-0bf5-44eb-b0a0-c9f1e1983a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9109224-9be5-4375-b761-58e54696796b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b45d7eba-0bf5-44eb-b0a0-c9f1e1983a13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2fe258a3-ca5d-466e-9ac1-fcea566e0817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9109224-9be5-4375-b761-58e54696796b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2fe258a3-ca5d-466e-9ac1-fcea566e0817" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_b8f3c763-9c09-4e8a-a2d3-9b9174bb9cf6" xlink:href="abus-20201231.xsd#abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9109224-9be5-4375-b761-58e54696796b" xlink:to="loc_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_b8f3c763-9c09-4e8a-a2d3-9b9174bb9cf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a8397d87-fc89-41e0-9cd5-b8aad8133aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9109224-9be5-4375-b761-58e54696796b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a8397d87-fc89-41e0-9cd5-b8aad8133aa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a76464d3-af15-4ae8-abf4-9ff2196ab36b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9109224-9be5-4375-b761-58e54696796b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a76464d3-af15-4ae8-abf4-9ff2196ab36b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_645c8a4d-bf15-4bab-af09-68b67d5d4f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8720dbc4-1a7e-4caf-bce3-58c68da1ba13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_645c8a4d-bf15-4bab-af09-68b67d5d4f8d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8720dbc4-1a7e-4caf-bce3-58c68da1ba13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0a81294c-cc14-4641-bb9a-5c6efd57a83b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_645c8a4d-bf15-4bab-af09-68b67d5d4f8d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0a81294c-cc14-4641-bb9a-5c6efd57a83b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ProceedsFromSaleOfFutureRoyaltiesNet_77d18bf8-be1e-4f65-ad15-2b2d4f9ff1dc" xlink:href="abus-20201231.xsd#abus_ProceedsFromSaleOfFutureRoyaltiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_645c8a4d-bf15-4bab-af09-68b67d5d4f8d" xlink:to="loc_abus_ProceedsFromSaleOfFutureRoyaltiesNet_77d18bf8-be1e-4f65-ad15-2b2d4f9ff1dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/Organization" xlink:type="simple" xlink:href="abus-20201231.xsd#Organization"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/Organization" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/OrganizationDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#OrganizationDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/OrganizationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/Significantaccountingpolicies" xlink:type="simple" xlink:href="abus-20201231.xsd#Significantaccountingpolicies"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/Significantaccountingpolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="abus-20201231.xsd#SignificantaccountingpoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesTables" xlink:type="simple" xlink:href="abus-20201231.xsd#SignificantaccountingpoliciesTables"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesNarrativeDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#SignificantaccountingpoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesEstimatedusefullivesofpropertyandequipmentDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#SignificantaccountingpoliciesEstimatedusefullivesofpropertyandequipmentDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesEstimatedusefullivesofpropertyandequipmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesComputationofbasicanddilutednetincomelosspercommonshareDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#SignificantaccountingpoliciesComputationofbasicanddilutednetincomelosspercommonshareDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesComputationofbasicanddilutednetincomelosspercommonshareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#SignificantaccountingpoliciesDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/Fairvaluemeasurements" xlink:type="simple" xlink:href="abus-20201231.xsd#Fairvaluemeasurements"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/Fairvaluemeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/FairvaluemeasurementsTables" xlink:type="simple" xlink:href="abus-20201231.xsd#FairvaluemeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/FairvaluemeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#FairvaluemeasurementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/FairvaluemeasurementsAssetsandliabilitiesmeasuredatfairvalueonrecurringbasisDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#FairvaluemeasurementsAssetsandliabilitiesmeasuredatfairvalueonrecurringbasisDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/FairvaluemeasurementsAssetsandliabilitiesmeasuredatfairvalueonrecurringbasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2d6e3023-d789-4447-ae58-be451cbb0201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_af664c47-962a-4564-bbca-8c26019a7001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_2d6e3023-d789-4447-ae58-be451cbb0201" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_af664c47-962a-4564-bbca-8c26019a7001" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ecc0fcb9-bd9f-44d8-9879-4a9e5ea10f62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_2d6e3023-d789-4447-ae58-be451cbb0201" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ecc0fcb9-bd9f-44d8-9879-4a9e5ea10f62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0adfe567-a388-4ff4-9e72-d1157d55a304" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2e0b025d-ed6d-4757-ac04-fb9ab591069e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_0adfe567-a388-4ff4-9e72-d1157d55a304" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2e0b025d-ed6d-4757-ac04-fb9ab591069e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_c4f8cb4f-50ed-48f3-a353-7a8f52c03c1a" xlink:href="abus-20201231.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_0adfe567-a388-4ff4-9e72-d1157d55a304" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_c4f8cb4f-50ed-48f3-a353-7a8f52c03c1a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/FairvaluemeasurementsChangesinfairvalueofliabilitiesclassifiedasstockoptionDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#FairvaluemeasurementsChangesinfairvalueofliabilitiesclassifiedasstockoptionDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/FairvaluemeasurementsChangesinfairvalueofliabilitiesclassifiedasstockoptionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/FairvaluemeasurementsChangesinfairvalueofcontingentconsiderationDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#FairvaluemeasurementsChangesinfairvalueofcontingentconsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/FairvaluemeasurementsChangesinfairvalueofcontingentconsiderationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/Investmentsinmarketablesecurities" xlink:type="simple" xlink:href="abus-20201231.xsd#Investmentsinmarketablesecurities"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/Investmentsinmarketablesecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/InvestmentsinmarketablesecuritiesTables" xlink:type="simple" xlink:href="abus-20201231.xsd#InvestmentsinmarketablesecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/InvestmentsinmarketablesecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/InvestmentsinmarketablesecuritiesDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#InvestmentsinmarketablesecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/InvestmentsinmarketablesecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b21da642-2db3-4b93-99b9-4d2c95ac57e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_db485193-0172-4001-9367-50a752d33e4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b21da642-2db3-4b93-99b9-4d2c95ac57e6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_db485193-0172-4001-9367-50a752d33e4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0736db48-e2d6-4eff-9fe1-67cd7eddcf87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b21da642-2db3-4b93-99b9-4d2c95ac57e6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0736db48-e2d6-4eff-9fe1-67cd7eddcf87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ece3901f-a690-4049-a20c-cceb739f4a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b21da642-2db3-4b93-99b9-4d2c95ac57e6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ece3901f-a690-4049-a20c-cceb739f4a7f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/InvestmentinGenevant" xlink:type="simple" xlink:href="abus-20201231.xsd#InvestmentinGenevant"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/InvestmentinGenevant" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/InvestmentinGenevantDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#InvestmentinGenevantDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/InvestmentinGenevantDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/Leases" xlink:type="simple" xlink:href="abus-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/LeasesTables" xlink:type="simple" xlink:href="abus-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/LeasesLeasecostDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#LeasesLeasecostDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/LeasesLeasecostDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/LeasesMaturityofleaseliabilityDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#LeasesMaturityofleaseliabilityDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/LeasesMaturityofleaseliabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2b435bdc-581e-4eb4-b455-fd20ed9178e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_de05a976-332a-4b0b-9b9f-300b6c804282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2b435bdc-581e-4eb4-b455-fd20ed9178e7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_de05a976-332a-4b0b-9b9f-300b6c804282" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_48907426-9246-4b42-87e0-5eb0f0187662" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2b435bdc-581e-4eb4-b455-fd20ed9178e7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_48907426-9246-4b42-87e0-5eb0f0187662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b7548ee4-3bb0-42da-b8f9-2855fa6d38bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2b435bdc-581e-4eb4-b455-fd20ed9178e7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b7548ee4-3bb0-42da-b8f9-2855fa6d38bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_672034cb-1872-4071-930a-593830518bcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2b435bdc-581e-4eb4-b455-fd20ed9178e7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_672034cb-1872-4071-930a-593830518bcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0423c780-9ad2-4ad7-bf5c-ec0579ec0c99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2b435bdc-581e-4eb4-b455-fd20ed9178e7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0423c780-9ad2-4ad7-bf5c-ec0579ec0c99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_19cdef88-b240-4951-8015-59584665f032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2b435bdc-581e-4eb4-b455-fd20ed9178e7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_19cdef88-b240-4951-8015-59584665f032" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/LeasesMaturityofleaseliabilityDetails_1" xlink:type="simple" xlink:href="abus-20201231.xsd#LeasesMaturityofleaseliabilityDetails_1"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/LeasesMaturityofleaseliabilityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_56dbc0c9-400a-4120-9de5-8d9daf9db347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_afa17ed0-dbf9-463f-9bd6-d00a5fd9211e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_56dbc0c9-400a-4120-9de5-8d9daf9db347" xlink:to="loc_us-gaap_OperatingLeaseLiability_afa17ed0-dbf9-463f-9bd6-d00a5fd9211e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7b47700e-1a7e-497e-9da3-862d37d5b8b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_56dbc0c9-400a-4120-9de5-8d9daf9db347" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7b47700e-1a7e-497e-9da3-862d37d5b8b6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/Propertyandequipment" xlink:type="simple" xlink:href="abus-20201231.xsd#Propertyandequipment"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/Propertyandequipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/PropertyandequipmentTables" xlink:type="simple" xlink:href="abus-20201231.xsd#PropertyandequipmentTables"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/PropertyandequipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/PropertyandequipmentScheduleDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#PropertyandequipmentScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/PropertyandequipmentScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4a3242c9-a3d0-4933-b156-8adb530a4f11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_51b2eb6e-5a65-4388-8495-76fd2c151152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4a3242c9-a3d0-4933-b156-8adb530a4f11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_51b2eb6e-5a65-4388-8495-76fd2c151152" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_062d87f0-4849-47d6-b035-af58ae95c74a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4a3242c9-a3d0-4933-b156-8adb530a4f11" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_062d87f0-4849-47d6-b035-af58ae95c74a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/PropertyandequipmentNarrativeDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#PropertyandequipmentNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/PropertyandequipmentNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/Intangibleassetsandgoodwill" xlink:type="simple" xlink:href="abus-20201231.xsd#Intangibleassetsandgoodwill"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/Intangibleassetsandgoodwill" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/IntangibleassetsandgoodwillDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#IntangibleassetsandgoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/IntangibleassetsandgoodwillDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/Accountspayableandaccruedliabilities" xlink:type="simple" xlink:href="abus-20201231.xsd#Accountspayableandaccruedliabilities"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/Accountspayableandaccruedliabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/AccountspayableandaccruedliabilitiesTables" xlink:type="simple" xlink:href="abus-20201231.xsd#AccountspayableandaccruedliabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/AccountspayableandaccruedliabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/AccountspayableandaccruedliabilitiesDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#AccountspayableandaccruedliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/AccountspayableandaccruedliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aeac20af-2a25-41ac-bb96-6de5ac078281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_c9abd3b4-428c-44a9-9de3-1df45d4a7ebe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aeac20af-2a25-41ac-bb96-6de5ac078281" xlink:to="loc_us-gaap_RestructuringReserve_c9abd3b4-428c-44a9-9de3-1df45d4a7ebe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_74eb02cc-f385-488d-bd6c-578fbce7248e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aeac20af-2a25-41ac-bb96-6de5ac078281" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_74eb02cc-f385-488d-bd6c-578fbce7248e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AccruedPayrollCurrent_74f29da5-7032-4998-a3d3-0b1412fbbb31" xlink:href="abus-20201231.xsd#abus_AccruedPayrollCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aeac20af-2a25-41ac-bb96-6de5ac078281" xlink:to="loc_abus_AccruedPayrollCurrent_74f29da5-7032-4998-a3d3-0b1412fbbb31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_d3fc3141-26b8-4b56-a232-58469d6962f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aeac20af-2a25-41ac-bb96-6de5ac078281" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_d3fc3141-26b8-4b56-a232-58469d6962f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_ec78bc4d-13ac-41c3-9231-cde3c3e14ad8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aeac20af-2a25-41ac-bb96-6de5ac078281" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_ec78bc4d-13ac-41c3-9231-cde3c3e14ad8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AccruedResearchandDevelopmentCurrent_56feacc9-4491-4453-8c44-cc8a6cc252a9" xlink:href="abus-20201231.xsd#abus_AccruedResearchandDevelopmentCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aeac20af-2a25-41ac-bb96-6de5ac078281" xlink:to="loc_abus_AccruedResearchandDevelopmentCurrent_56feacc9-4491-4453-8c44-cc8a6cc252a9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/Saleoffutureroyalties" xlink:type="simple" xlink:href="abus-20201231.xsd#Saleoffutureroyalties"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/Saleoffutureroyalties" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SaleoffutureroyaltiesTables" xlink:type="simple" xlink:href="abus-20201231.xsd#SaleoffutureroyaltiesTables"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SaleoffutureroyaltiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SaleoffutureroyaltiesNarrativeDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#SaleoffutureroyaltiesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SaleoffutureroyaltiesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SaleoffutureroyaltiesActivityDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#SaleoffutureroyaltiesActivityDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SaleoffutureroyaltiesActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/Contingenciesandcommitments" xlink:type="simple" xlink:href="abus-20201231.xsd#Contingenciesandcommitments"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/Contingenciesandcommitments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesandcommitmentsDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#ContingenciesandcommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesandcommitmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/Collaborationscontractsandlicensingagreements" xlink:type="simple" xlink:href="abus-20201231.xsd#Collaborationscontractsandlicensingagreements"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/Collaborationscontractsandlicensingagreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationscontractsandlicensingagreementsTables" xlink:type="simple" xlink:href="abus-20201231.xsd#CollaborationscontractsandlicensingagreementsTables"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationscontractsandlicensingagreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationscontractsandlicensingagreementsNarrativeDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#CollaborationscontractsandlicensingagreementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationscontractsandlicensingagreementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationscontractsandlicensingagreementsSummaryofrevenuesDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#CollaborationscontractsandlicensingagreementsSummaryofrevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationscontractsandlicensingagreementsSummaryofrevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/Shareholdersequity" xlink:type="simple" xlink:href="abus-20201231.xsd#Shareholdersequity"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/Shareholdersequity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ShareholdersequityDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#ShareholdersequityDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareholdersequityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/Stockbasedcompensation" xlink:type="simple" xlink:href="abus-20201231.xsd#Stockbasedcompensation"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/Stockbasedcompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationTables" xlink:type="simple" xlink:href="abus-20201231.xsd#StockbasedcompensationTables"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/StockbasedcompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationNarrativeDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#StockbasedcompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/StockbasedcompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationStockoptionactivityundertheArbutusPlanDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#StockbasedcompensationStockoptionactivityundertheArbutusPlanDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/StockbasedcompensationStockoptionactivityundertheArbutusPlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationStockoptionsoutstandingundertheArbutusPlanDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#StockbasedcompensationStockoptionsoutstandingundertheArbutusPlanDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/StockbasedcompensationStockoptionsoutstandingundertheArbutusPlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationValuationassumptionsforstockoptionsundertheArbutusPlanDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#StockbasedcompensationValuationassumptionsforstockoptionsundertheArbutusPlanDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/StockbasedcompensationValuationassumptionsforstockoptionsundertheArbutusPlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationStockoptionactivityforliabilityclassifiedoptionsDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#StockbasedcompensationStockoptionactivityforliabilityclassifiedoptionsDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/StockbasedcompensationStockoptionactivityforliabilityclassifiedoptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationValuationassumptionsforliabilityclassifiedoptionsDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#StockbasedcompensationValuationassumptionsforliabilityclassifiedoptionsDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/StockbasedcompensationValuationassumptionsforliabilityclassifiedoptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationOutstandingoptionsundertheOncoreOptionPlanDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#StockbasedcompensationOutstandingoptionsundertheOncoreOptionPlanDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/StockbasedcompensationOutstandingoptionsundertheOncoreOptionPlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationStockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#StockbasedcompensationStockbasedcompensationexpenseDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/StockbasedcompensationStockbasedcompensationexpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/Incometaxes" xlink:type="simple" xlink:href="abus-20201231.xsd#Incometaxes"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/Incometaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/IncometaxesTables" xlink:type="simple" xlink:href="abus-20201231.xsd#IncometaxesTables"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/IncometaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/IncometaxesNarrativeDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#IncometaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/IncometaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/IncometaxesIncometaxreconciliationDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#IncometaxesIncometaxreconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/IncometaxesIncometaxreconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11a265bd-6d2c-486e-b2cc-8ba9d2cbe564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_4c78fc28-df42-447d-9094-4efaf9298deb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_11a265bd-6d2c-486e-b2cc-8ba9d2cbe564" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_4c78fc28-df42-447d-9094-4efaf9298deb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_f6db4e7b-1a60-4432-8237-abeb1c8ed86b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_11a265bd-6d2c-486e-b2cc-8ba9d2cbe564" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_f6db4e7b-1a60-4432-8237-abeb1c8ed86b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_09b7035b-5044-4a96-a4d6-3076621f3910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_11a265bd-6d2c-486e-b2cc-8ba9d2cbe564" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_09b7035b-5044-4a96-a4d6-3076621f3910" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_43b653bf-1f69-4dbf-aace-8c08bd522666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_11a265bd-6d2c-486e-b2cc-8ba9d2cbe564" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_43b653bf-1f69-4dbf-aace-8c08bd522666" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_36f3fc46-9048-4537-b8ca-f439ed811247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_11a265bd-6d2c-486e-b2cc-8ba9d2cbe564" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_36f3fc46-9048-4537-b8ca-f439ed811247" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2dd12d8d-2987-4cb1-b1ed-f3de73088a64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_11a265bd-6d2c-486e-b2cc-8ba9d2cbe564" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2dd12d8d-2987-4cb1-b1ed-f3de73088a64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9ff09639-04fc-4564-996f-99f8aceccd26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_11a265bd-6d2c-486e-b2cc-8ba9d2cbe564" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9ff09639-04fc-4564-996f-99f8aceccd26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_6e486305-5881-4513-8687-7bc801ceba51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_11a265bd-6d2c-486e-b2cc-8ba9d2cbe564" xlink:to="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_6e486305-5881-4513-8687-7bc801ceba51" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/IncometaxesDeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#IncometaxesDeferredtaxassetsandliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/IncometaxesDeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_f505b534-3ef4-4eba-93b9-756488c42d85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_DeferredTaxAssetsLiabilitiesGross_20ba7428-39b2-4442-a5a6-233dd380c9b6" xlink:href="abus-20201231.xsd#abus_DeferredTaxAssetsLiabilitiesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_f505b534-3ef4-4eba-93b9-756488c42d85" xlink:to="loc_abus_DeferredTaxAssetsLiabilitiesGross_20ba7428-39b2-4442-a5a6-233dd380c9b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0bfaf7be-cc0e-4f93-aa18-8f9e6624f2c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_f505b534-3ef4-4eba-93b9-756488c42d85" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0bfaf7be-cc0e-4f93-aa18-8f9e6624f2c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_DeferredTaxAssetsLiabilitiesGross_ccccdcc0-5d0d-4124-a7c3-894dfe2d84aa" xlink:href="abus-20201231.xsd#abus_DeferredTaxAssetsLiabilitiesGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions_950aa115-9b3b-4348-9913-3f45d46afc30" xlink:href="abus-20201231.xsd#abus_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_ccccdcc0-5d0d-4124-a7c3-894dfe2d84aa" xlink:to="loc_abus_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions_950aa115-9b3b-4348-9913-3f45d46afc30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_bf7c2789-612a-4ea9-9c3e-5375ed9ec512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_ccccdcc0-5d0d-4124-a7c3-894dfe2d84aa" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_bf7c2789-612a-4ea9-9c3e-5375ed9ec512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7d1ba7ca-1970-4bde-abe6-fd5437378f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_ccccdcc0-5d0d-4124-a7c3-894dfe2d84aa" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7d1ba7ca-1970-4bde-abe6-fd5437378f80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_b89fb09b-e25b-4638-a855-5e9ca7ded31d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_ccccdcc0-5d0d-4124-a7c3-894dfe2d84aa" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_b89fb09b-e25b-4638-a855-5e9ca7ded31d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_d3c6ca89-f832-4fa5-b096-aea991b3df40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_ccccdcc0-5d0d-4124-a7c3-894dfe2d84aa" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_d3c6ca89-f832-4fa5-b096-aea991b3df40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_50f526b5-83fe-4f79-bce6-63bd8ed9e3a8" xlink:href="abus-20201231.xsd#abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_ccccdcc0-5d0d-4124-a7c3-894dfe2d84aa" xlink:to="loc_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_50f526b5-83fe-4f79-bce6-63bd8ed9e3a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_61365f00-720a-4c9e-be6f-ef851b4ff83c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_ccccdcc0-5d0d-4124-a7c3-894dfe2d84aa" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_61365f00-720a-4c9e-be6f-ef851b4ff83c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_61c4232d-32ee-4c6f-bd71-c20041378d2a" xlink:href="abus-20201231.xsd#abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_ccccdcc0-5d0d-4124-a7c3-894dfe2d84aa" xlink:to="loc_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_61c4232d-32ee-4c6f-bd71-c20041378d2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_1e57f7f7-5a8d-4de1-a206-9c68914cafbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_ccccdcc0-5d0d-4124-a7c3-894dfe2d84aa" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_1e57f7f7-5a8d-4de1-a206-9c68914cafbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_75166035-9cb1-4a22-aba5-4ccf75e02fb7" xlink:href="abus-20201231.xsd#abus_DeferredTaxAssetBookAmortizationInExcessOfTax"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_DeferredTaxAssetsLiabilitiesGross_ccccdcc0-5d0d-4124-a7c3-894dfe2d84aa" xlink:to="loc_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_75166035-9cb1-4a22-aba5-4ccf75e02fb7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/Relatedpartytransactions" xlink:type="simple" xlink:href="abus-20201231.xsd#Relatedpartytransactions"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/Relatedpartytransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/RelatedpartytransactionsDetails" xlink:type="simple" xlink:href="abus-20201231.xsd#RelatedpartytransactionsDetails"/>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/RelatedpartytransactionsDetails" xlink:type="extended"/>
</link:linkbase>
